About Stereotaxis (OTCMKTS:STXS)
Stereotaxis, Inc. is a United States-based healthcare technology company. The Company is engaged in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease. The Company also provides information management solutions for the interventional lab. The Stereotaxis platform helps physicians to provide patient care with robotic precision and enhanced integration of procedural information. The Company's Epoch solution includes the Niobe ES remote magnetic navigation system, the Odyssey portfolio of lab optimization, networking and patient information management systems, and the Vdrive robotic navigation system and consumables. The Niobe ES remote magnetic navigation system includes the Navigant software user interface and the QuikCAS catheter advancement system. The Vdrive robotic navigation system with Niobe ES magnetic navigation system provides navigation and stability for diagnostic and ablation devices.
Industry, Sector and Symbol
Industry Medical Appliances & Equipment
SymbolOTCMKTS:STXSPrevious Symbol: NASDAQ:STXS
Trailing P/E Ratio3.71
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$32.16 million
Price / Sales0.55
Price / CashN/A
Book Value($1.06) per share
Price / Book-0.74
Return on Equity-30.95%
Return on Assets36.99%
Frequently Asked Questions for Stereotaxis (OTCMKTS:STXS)
What is Stereotaxis' stock symbol?
Stereotaxis trades on the OTCMKTS under the ticker symbol "STXS."
How were Stereotaxis' earnings last quarter?
Stereotaxis Inc. (OTCMKTS:STXS) posted its quarterly earnings data on Monday, May, 9th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter. The medical equipment provider earned $8.60 million during the quarter, compared to the consensus estimate of $9.50 million. Stereotaxis had a net margin of 7.12% and a negative return on equity of 30.95%. View Stereotaxis' Earnings History.
When will Stereotaxis make its next earnings announcement?
Who are some of Stereotaxis' key competitors?
Some companies that are related to Stereotaxis include EnteroMedics (RSLS), Valeritas Holdings (VLRX), Genocea Biosciences (GNCA), Vical Incorporated (VICL), AEterna Zentaris (AEZS), Caladrius Biosciences (CLBS), Azurrx Biopharm (AZRX), Proteon Therapeutics (PRTO), Oncobiologics (ONS), Pernix Therapeutics Holdings (PTX), Tonix Pharmaceuticals Holding Corp. (TNXP), Trimel Pharmaceuticals Corp. (TRLPF), Interpace Diagnostics Group (IDXG), Bio-Path Holdings (BPTH), Intellipharmaceutics International (IPCI), Tokai Pharmaceuticals (NVUS), Anthera Pharmaceuticals (ANTH) and Prana Biotechnology Ltd (PRAN).
Who are Stereotaxis' key executives?
Stereotaxis' management team includes the folowing people:
- David Fischel, Chairman of the Board, Acting Chief Executive Officer (Age 30)
- Martin C. Stammer, Chief Financial Officer (Age 36)
- Karen W. Duros, Senior Vice President, General Counsel, Secretary (Age 62)
- David A. Giffin, Vice President - Human Resources (Age 68)
- Paul A. Brathwaite Ph.D., Vice President - Research & Development (Age 47)
- Joseph E. Kiani, Director (Age 52)
- Arun Swarup Menawat Ph.D., Director (Age 62)
- David W. Benfer, Independent Director (Age 70)
- Nathan Fischel M.D., Independent Director (Age 61)
- Robert J. Messey, Independent Director (Age 71)
How do I buy Stereotaxis stock?
Shares of Stereotaxis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stereotaxis' stock price today?
One share of Stereotaxis stock can currently be purchased for approximately $0.78.
How big of a company is Stereotaxis?
Stereotaxis has a market capitalization of $17.78 million and generates $32.16 million in revenue each year. The medical equipment provider earns $-5,280,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Stereotaxis employs 120 workers across the globe.
How can I contact Stereotaxis?
Stereotaxis' mailing address is 4320 Forest Park Avenue Suite 100, ST.LOUIS MO, 63108. The medical equipment provider can be reached via phone at 314-678-6100 or via email at [email protected]
MarketBeat Community Rating for Stereotaxis (STXS)MarketBeat's community ratings are surveys of what our community members think about Stereotaxis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Stereotaxis (OTCMKTS:STXS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Stereotaxis (OTCMKTS:STXS)
Analysts' Ratings History for Stereotaxis (OTCMKTS:STXS)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History and Estimates Chart for Stereotaxis (OTCMKTS:STXS)
Earnings History by Quarter for Stereotaxis (OTCMKTS STXS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/15/2018|| || || || || || || || |
|8/10/2017||Q2 2017||($0.02)||$8.47 million||View||N/A|
|5/8/2017||Q1 2017||$0.01||$6.98 million||View||Listen|
|5/9/2016||Q1||($0.11)||$9.50 million||$8.60 million||View||Listen|
|2/22/2016||Q4||($0.10)||$9.80 million||$9.20 million||View||Listen|
|11/3/2015||Q3||($0.05)||$8.90 million||$9.30 million||View||Listen|
|8/4/2015||Q215||($0.12)||$120.60 million||$9.66 million||View||N/A|
|5/6/2015||Q115||($0.15)||$8.40 million||$9.50 million||View||Listen|
|2/25/2015||Q414||$0.04||$9.10 million||$9.80 million||View||Listen|
|5/6/2014||Q1||($0.16)||$8.40 million||$8.40 million||View||Listen|
|2/25/2014||Q4||($0.19)||$12.20 million||$9.10 million||View||Listen|
|11/12/2013||Q3||($0.26)||$9.70 million||$10.80 million||View||N/A|
|8/8/2013||Q2 2013||($0.59)||($0.37)||$10.80 million||$9.70 million||View||Listen|
|5/13/2013||Q1 2013||($0.50)||($0.61)||$12.00 million||$8.40 million||View||Listen|
|11/5/2012||Q312||($0.72)||($0.33)||$10.30 million||$11.60 million||View||N/A|
Earnings Estimates for Stereotaxis (OTCMKTS:STXS)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Stereotaxis (OTCMKTS:STXS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Stereotaxis (OTCMKTS STXS)
Insider Ownership Percentage: 22.05%
Institutional Ownership Percentage: 6.08%
Insider Trades by Quarter for Stereotaxis (OTCMKTS STXS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/15/2015||Fred A Middleton||Director||Sell||26,064||$1.57||$40,920.48|| |
|6/12/2015||Fred A Middleton||Director||Sell||16,273||$1.61||$26,199.53|| |
|6/9/2015||Fred A Middleton||Director||Sell||106,876||$1.65||$176,345.40|| |
|3/13/2015||David Benfer||Director||Buy||3,000||$1.95||$5,850.00|| |
|12/12/2014||William C Mills III||CEO||Buy||10,000||$1.45||$14,500.00|| |
|12/9/2014||Fred A Middleton||Director||Sell||8,551||$1.51||$12,912.01|| |
|12/5/2014||William C Mills III||CEO||Buy||10,000||$1.43||$14,300.00|| |
|12/3/2014||Fred A Middleton||Director||Sell||15,809||$1.59||$25,136.31|| |
|8/11/2014||William C Mills III||CEO||Buy||10,000||$2.75||$27,500.00|| |
|3/13/2014||Fred A Middleton||Director||Sell||24,302||$4.21||$102,311.42|| |
|8/23/2013||Fred A Middleton||Director||Sell||14,600||$3.67||$53,582.00|| |
|8/20/2013||Christopher D Alafi||Major Shareholder||Sell||261,241||$3.74||$977,041.34|| |
|8/7/2013||Fred A Middleton||Director||Sell||78,974||$10.13||$800,006.62|| |
|11/30/2012||Fred A Middleton||Director||Buy||24,360||$1.53||$37,270.80|| |
Latest Headlines for Stereotaxis (OTCMKTS STXS)
Stereotaxis (OTCMKTS STXS) Chart for Friday, November, 24, 2017